OIM
CAPR icon

Oracle Investment Management’s Capricor Therapeutics CAPR Stock Holding History

Oracle Investment Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,166,249
Closed -$5.98M – 41
2021
Q2 		$5.98M Sell
1,166,249
-833,215
-42% -$3.53M 0.82% 17
2021
Q1 		$9.36M Buy
+1,999,464
New +$11.5M 1.4% 13

Other funds holding CAPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Oracle Investment Management's CAPR Position: Q3 2021 in Review

Oracle Investment Management sold out of Capricor Therapeutics (CAPR) in Q3 2021, closing a stake of 1,166,249 shares — an estimated $5.98M sold.

Oracle Investment Management first reported a position in CAPR in Q1 2021 and held it in 2 quarters. The position peaked at $9.36M in Q1 2021. 30 funds tracked by Wall St. Rank hold CAPR as of Q3 2021.

  • Oracle Investment Management reported no remaining Capricor Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Oracle Investment Management sold 1,166,249 Capricor Therapeutics shares in Q3 2021, an estimated $5.98M.
  • Oracle Investment Management first reported a position in Capricor Therapeutics in Q1 2021 and held it in 2 quarters.
  • Oracle Investment Management's Capricor Therapeutics position peaked at $9.36M in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2021.

Based on Oracle Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.